Terms: = Lymphoma AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Prognosis
17 results:
1. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
[TBL] [Abstract] [Full Text] [Related]
2. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract] [Full Text] [Related]
3. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract] [Full Text] [Related]
4. Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
Ma G; Gao Y; Jing X; He C; Liu H; Wu X; Gao Z; Li Y; Zhang S; Zhao G
Leuk Lymphoma; 2023 Jan; 64(1):140-150. PubMed ID: 36215154
[TBL] [Abstract] [Full Text] [Related]
5. sf3b1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
[TBL] [Abstract] [Full Text] [Related]
6. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and sf3b1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
[TBL] [Abstract] [Full Text] [Related]
7. Excellent prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract] [Full Text] [Related]
8. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract] [Full Text] [Related]
9. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Hernández-Sánchez JM; Vidal MJ; de Coca AG; Aguilar C; Vargas-Pabón M; Alonso S; Sierra M; Rubio-Martínez A; Dávila J; Díaz-Valdés JR; Queizán JA; Hernández-Rivas JÁ; Benito R; Rodríguez-Vicente AE; Hernández-Rivas JM
Int J Cancer; 2020 Nov; 147(10):2780-2792. PubMed ID: 32720348
[TBL] [Abstract] [Full Text] [Related]
10. sf3b1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract] [Full Text] [Related]
11. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Outcomes With Ring Sideroblasts and sf3b1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract] [Full Text] [Related]
13. Diagnosis and classification of hematologic malignancies on the basis of genetics.
Taylor J; Xiao W; Abdel-Wahab O
Blood; 2017 Jul; 130(4):410-423. PubMed ID: 28600336
[TBL] [Abstract] [Full Text] [Related]
14. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract] [Full Text] [Related]
15. The impact of sf3b1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
Rosenquist R; Cortese D; Bhoi S; Mansouri L; Gunnarsson R
Leuk Lymphoma; 2013 Nov; 54(11):2351-64. PubMed ID: 23480493
[TBL] [Abstract] [Full Text] [Related]
17. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies.
Gunnarsson R; Mansouri L; Rosenquist R
Leuk Lymphoma; 2013 Aug; 54(8):1583-90. PubMed ID: 23167608
[TBL] [Abstract] [Full Text] [Related]
